All In Biotech

Drug Trial Radar · NCT01511289

Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

A Phase 3 Multinational, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Ph+ CML Patients in Early Chronic Phase

Last checked: Nov 19, 2026Latest source record: Feb 24, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 242 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

242

Actual

Start

Aug 2011

Primary completion

Feb 2015

Sponsor

Lead sponsor
Il-Yang Pharm. Co., Ltd.Industry
Sponsor type
Industry
First posted
Jan 18, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, the efficacy and safety of two radotinib doses, 300 mg twice daily and 400 mg twice daily, will be compared with imatinib 400 mg once daily in newly diagnosed patients with Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase (CML-CP).

Conditions

  • Leukemia
  • Leukemia, Myeloid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Philadelphia Chromosome
  • Bone Marrow Diseases
  • Hematologic Diseases

Interventions

  • ImatinibDrug

    400mg/Tab, QD

  • RadotinibDrug

    100mg or 200mg/Capsule, 300mg or 400mg BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Major Molecular Response(MMR) by 12 monthsTime frame: 12 months

Locations

22 sites in 4 countries. Site status is shown where the registry gives one.

  • Local Institution

    Jakarta, Indonesia

  • Local Institution

    Batangas, Philippines

  • Local Institution

    Manila, Philippines

  • Local Institution

    Busan, South Korea

  • Local Institution

    Busan, South Korea

  • Local Institution

    Busan, South Korea

  • Local Institution

    Daegu, South Korea

  • Local Institution

    Daejeon, South Korea

  • Local Institution

    Gyeonggi-do, South Korea

  • Local Institution

    Gyeonggi-do, South Korea

  • Local Institution

    Gyeonggi-do, South Korea

  • Local Institution

    Incheon, South Korea

  • Local Institution

    Jeollabuk-do, South Korea

  • Local Institution

    Jeonnam, South Korea

  • Local Institution

    Seoul, South Korea

  • Local Institution

    Seoul, South Korea

  • Local Institution

    Seoul, South Korea

  • Local Institution

    Seoul, South Korea

  • Local Institution

    Seoul, South Korea

  • Local Institution

    Ulsan, South Korea

  • Local Institution

    Wŏnju, South Korea

  • Local Institution

    Bangkok, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.